These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 10404769)

  • 1. Increased C-reactive protein levels during short-term hormone replacement therapy in healthy postmenopausal women.
    van Baal WM; Kenemans P; van der Mooren MJ; Kessel H; Emeis JJ; Stehouwer CD
    Thromb Haemost; 1999 Jun; 81(6):925-8. PubMed ID: 10404769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-term effects of two continuous combined oestrogen-progestogen therapies on several cardiovascular risk markers in healthy postmenopausal women: a randomised controlled trial.
    de Kraker AT; Kenemans P; Smolders RG; Kroeks MV; van der Mooren MJ
    Eur J Obstet Gynecol Reprod Biol; 2009 Feb; 142(2):139-44. PubMed ID: 19095343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impaired procoagulant-anticoagulant balance during hormone replacement therapy? A randomised, placebo-controlled 12-week study.
    van Baal WM; Emeis JJ; van der Mooren MJ; Kessel H; Kenemans P; Stehouwer CD
    Thromb Haemost; 2000 Jan; 83(1):29-34. PubMed ID: 10669150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women.
    Post MS; Christella M; Thomassen LG; van der Mooren MJ; van Baal WM; Rosing J; Kenemans P; Stehouwer CD
    Arterioscler Thromb Vasc Biol; 2003 Jun; 23(6):1116-21. PubMed ID: 12730085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of intranasal 17beta-estradiol administration on serum bioactive interleukin-6 and C-reactive protein levels in healthy postmenopausal women.
    Rachoń D; Suchecka-Rachoń K; Hak Ł; Myśliwska J
    Menopause; 2006; 13(5):840-5. PubMed ID: 16894332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No increase in C-reactive protein levels during intranasal compared to oral hormone therapy in healthy post-menopausal women.
    Hemelaar M; Kenemans P; Schalkwijk CG; Braat DD; van der Mooren MJ
    Hum Reprod; 2006 Jun; 21(6):1635-42. PubMed ID: 16501036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of the phytoestrogen genistein and hormone replacement therapy on homocysteine and C-reactive protein level in postmenopausal women.
    D'Anna R; Baviera G; Corrado F; Cancellieri F; Crisafulli A; Squadrito F
    Acta Obstet Gynecol Scand; 2005 May; 84(5):474-7. PubMed ID: 15842212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the route of estrogen administration on insulinlike growth factor-I, IGF binding protein-3, and insulin resistance in healthy postmenopausal women: results from a randomized, controlled study.
    Davis SR; Stuckey BG; Norman RJ; Papalia MA; Drillich A; Bell RJ
    Menopause; 2008; 15(6):1065-9. PubMed ID: 18806686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Value of C-reactive protein levels and IL-6 in predicting events levels in women at increased cardiovascular risk.
    Vitale C; Gebara O; Mercuro G; Wajngarten M; Silvestri A; Rossini P; Ramires JA; Fini M; Rosano GM
    Maturitas; 2005 Apr; 50(4):239-46. PubMed ID: 15780522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women.
    Zegura B; Guzic-Salobir B; Sebestjen M; Keber I
    Menopause; 2006; 13(4):643-50. PubMed ID: 16837886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of estrogen, raloxifene, and hormone replacement therapy on serum C-reactive protein and homocysteine levels.
    Gol M; Akan P; Dogan E; Karas C; Saygili U; Posaci C
    Maturitas; 2006 Feb; 53(3):252-9. PubMed ID: 15990257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of progestins on estrogen-induced increase in C-reactive protein in postmenopausal women.
    Rossi R; Bursi F; Veronesi B; Cagnacci A; Modena MG
    Maturitas; 2004 Dec; 49(4):315-20. PubMed ID: 15531127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of postmenopausal hormone replacement therapy on body fat composition.
    Yüksel H; Odabasi AR; Demircan S; Köseoğlu K; Kizilkaya K; Onur E
    Gynecol Endocrinol; 2007 Feb; 23(2):99-104. PubMed ID: 17454160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicentre randomised trial to compare uterine safety of raloxifene with a continuous combined hormone replacement therapy containing oestradiol and norethisterone acetate.
    Neven P; Lunde T; Benedetti-Panici P; Tiitinen A; Marinescu B; de Villiers T; Hillard T; Cano A; Peer E; Quail D; Nickelsen T;
    BJOG; 2003 Feb; 110(2):157-67. PubMed ID: 12618160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of oral and transdermal hormone replacement therapy on C-reactive protein levels and other inflammatory markers in women with high risk of thrombosis.
    Eilertsen AL; Høibraaten E; Os I; Andersen TO; Sandvik L; Sandset PM
    Maturitas; 2005 Oct; 52(2):111-8. PubMed ID: 16186073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral, more than transdermal, estrogen therapy improves lipids and lipoprotein(a) in postmenopausal women: a randomized, placebo-controlled study.
    Hemelaar M; van der Mooren MJ; Mijatovic V; Bouman AA; Schijf CP; Kroeks MV; Franke HR; Kenemans P
    Menopause; 2003; 10(6):550-8. PubMed ID: 14627865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic variation in estrogen receptor, C-reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after longterm hormone replacement therapy.
    de Maat MP; Madsen JS; Langdahl B; Bladbjerg EM; Tofteng CL; Abrahamsen B; Rejnmark L; Brixen K; Christensen K; Jespersen J; Kristensen SR
    Thromb Haemost; 2007 Feb; 97(2):234-9. PubMed ID: 17264952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-term effects of hormone therapy on serum C-reactive protein levels in postmenopausal women.
    Kiran H; Kiran G
    Arch Gynecol Obstet; 2006 Apr; 274(1):9-12. PubMed ID: 16369811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High C-reactive protein levels are associated with oral hormonal menopausal therapy but not with intrauterine levonorgestrel and transdermal estradiol.
    Blumenfeld Z; Boulman N; Leiba R; Siegler E; Shachar S; Linn R; Levy Y
    Scand J Clin Lab Invest; 2007; 67(3):257-63. PubMed ID: 17454839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of estrogen and androgen levels after oral estrogen replacement therapy.
    Slater CC; Zhang C; Hodis HN; Mack WJ; Boostanfar R; Shoupe D; Paulson RJ; Stanczyk FZ
    J Reprod Med; 2001 Dec; 46(12):1052-6. PubMed ID: 11789085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.